SG Americas Securities LLC Takes $34,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA)

SG Americas Securities LLC purchased a new position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 33,144 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Akebia Therapeutics by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 8,225,972 shares of the biopharmaceutical company’s stock valued at $15,054,000 after purchasing an additional 618,500 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Akebia Therapeutics in the first quarter valued at $1,447,000. Lazard Asset Management LLC acquired a new position in Akebia Therapeutics during the 1st quarter worth $79,000. Orchard Capital Management LLC increased its position in shares of Akebia Therapeutics by 29.9% in the 4th quarter. Orchard Capital Management LLC now owns 86,826 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Raymond James & Associates raised its stake in shares of Akebia Therapeutics by 48.0% in the 4th quarter. Raymond James & Associates now owns 29,917 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 9,696 shares in the last quarter. Hedge funds and other institutional investors own 33.92% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on Akebia Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Monday, August 12th.

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $1.52 on Wednesday. Akebia Therapeutics, Inc. has a 12 month low of $0.78 and a 12 month high of $2.48. The company has a fifty day moving average price of $1.24 and a two-hundred day moving average price of $1.35. The company has a market cap of $318.59 million, a PE ratio of -6.61 and a beta of 0.77.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business had revenue of $43.65 million during the quarter, compared to analyst estimates of $45.61 million. During the same period last year, the firm posted ($0.06) earnings per share. Equities research analysts anticipate that Akebia Therapeutics, Inc. will post -0.28 earnings per share for the current year.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.